Neurocentret Rigshospitalet

Medicin og biovidenskab

1. Migraine Disorders 100%
2. Multiple Sclerosis 85%
3. Headache 55%
4. Brain 48%
5. Denmark 42%
6. Alzheimer Disease 39%
7. Dementia 38%
8. Stroke 38%
9. Spinal Cord Injuries 37%
10. Therapeutics 36%
11. Sleep 34%
12. Traumatic Brain Injury 34%
13. Cerebrovascular Circulation 33%
14. Systematic Reviews 32%
15. Placebos 30%
16. Muscles 28%
17. Cerebrospinal Fluid 28%
18. Pain 27%
19. Cohort Studies 25%
20. Randomized Controlled Trials 25%
21. Biomarkers 25%
22. Population 25%
23. Cognitive Dysfunction 25%
24. Calcitonin Gene-Related Peptide 24%
25. Epilepsy 24%
26. Magnetic Resonance Imaging 24%
27. Cluster Headache 22%
28. Healthy Volunteers 21%
29. Positron-Emission Tomography 21%
30. Exercise 21%
31. Intracranial Pressure 19%
32. Brain Injuries 18%
33. Electroencephalography 18%
34. Receptor, Serotonin, 5-HT2A 18%
35. Mutation 18%
36. Genes 17%
37. Depression 16%
38. Cognition 16%
39. Subarachnoid Hemorrhage 16%
40. Mortality 16%
41. Narcolepsy 16%
42. Migraine with Aura 16%
43. White Matter 16%
44. Meta-Analysis 16%
45. Tension-Type Headache 15%
46. Secondary Headache Disorders 15%
47. Serotonin 15%
48. Relapsing-Remitting Multiple Sclerosis 15%
49. Guidelines 15%
50. Spinal Cord 15%
51. Rehabilitation 15%
52. Pharmaceutical Preparations 15%
53. Registries 14%
54. Child 14%
55. Confidence Intervals 14%
56. Phenotype 14%
57. Wounds and Injuries 14%
58. Glycogen Storage Disease Type V 13%
59. Memory 13%
60. Datasets 13%
61. Safety 13%
62. Neuroimaging 13%
63. Quality of Life 13%
64. Intensive Care Units 13%
65. Frontotemporal Dementia 13%
66. Migraine without Aura 12%
67. erenumab 12%
68. Headache Disorders 12%
69. Observational Studies 12%
70. Incidence 12%
71. REM Sleep Behavior Disorder 12%
72. Prospective Studies 12%
73. Pseudotumor Cerebri 12%
74. Seizures 11%
75. Meningioma 11%
76. Single-Photon Emission-Computed Tomography 11%
77. Parkinson Disease 11%
78. Multicenter Studies 11%
79. Health 11%
80. Elderly 11%
81. Optic Neuritis 10%
82. Bipolar Disorder 10%
83. Oxygen 10%
84. Sumatriptan 10%
85. Natalizumab 10%
86. Global Burden of Disease 10%
87. Neoplasms 10%
88. Schizophrenia 10%
89. Huntington Disease 10%
90. Genome-Wide Association Study 10%
91. Pharmacology 9%
92. Opioid Analgesics 9%
93. Recurrence 9%
94. Neurons 9%
95. Pituitary Adenylate Cyclase-Activating Polypeptide 9%
96. Homeostasis 9%
97. Cross-Over Studies 9%
98. Comorbidity 9%
99. Hydrocephalus 9%
100. Serotonin Plasma Membrane Transport Proteins 9%